Aktiesnakken — Marts 2011
-
nej munk i er fortsat for tidligt ude
-
GSK siger at uptake er suppresed og det er post rituxian
-
han køber nu fordi han tror på genmab på den lange bane, ikke spekulativt over et kvartal
-
og så har han et vindue
-
jeg tror på 20 mill her q1
-
og jeg holder fast ved 150 mill full year
-
20-25-45-60?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind